SCHEMBL7125726

SCHEMBL7125726

Cc1[nH]c(C=O)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 2/20 0.49
PDGFRB P09619 2/20 0.49
KIT P10721 2/20 0.49
KDR P35968 2/20 0.49
PLK4 O00444 1/20 0.49
RIOK3 O14730 1/20 0.49
CASK O14936 1/20 0.49
GAK O14976 1/20 0.49
DCLK1 O15075 1/20 0.49
EPHB6 O15197 1/20 0.49
MAP3K13 O43283 1/20 0.49
MAP3K7 O43318 1/20 0.49
NUAK1 O60285 1/20 0.49
JAK2 O60674 1/20 0.49
ROCK2 O75116 1/20 0.49
ULK1 O75385 1/20 0.49
RPS6KA5 O75582 1/20 0.49
STK16 O75716 1/20 0.49
PAK3 O75914 1/20 0.49
STK17B O94768 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7125733 1.00 MET (0.49) METPDGFRBKITKDRPLK4
SCHEMBL7117886 0.83 TDP1 (0.40) METPDGFRBKITKDRPLK4
SCHEMBL7117882 0.83 TDP1 (0.40) METPDGFRBKITKDRPLK4
SCHEMBL7117397 0.83 OPRK1 (0.43) BLMTDP1
SCHEMBL7117403 0.83 OPRK1 (0.43) BLMTDP1
SCHEMBL23903547 0.82 HRH3 (0.44) METPDGFRBKITKDRPLK4
SCHEMBL7124344 0.81 DPP4 (0.36) METPDGFRBKITKDRPLK4
SCHEMBL7124352 0.81 DPP4 (0.36) METPDGFRBKITKDRPLK4
SCHEMBL5628863 0.76 PDGFRB (0.56) METPDGFRBKITKDRPLK4
SCHEMBL5255325 0.76 PDGFRB (0.56) METPDGFRBKITKDRPLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US disclosed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US disclosed
WO-2002096361-A2 5-ARALKYLSULFONYL-3- (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. (US) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 MET 151/4885PDGFRB 348/4885KIT 502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.